<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1160">
  <stage>Registered</stage>
  <submitdate>13/03/2006</submitdate>
  <approvaldate>15/03/2006</approvaldate>
  <actrnumber>ACTRN12606000100594</actrnumber>
  <trial_identification>
    <studytitle>Baclofen for Alcohol Dependence</studytitle>
    <scientifictitle>The safety and efficacy of baclofen for alcohol dependence: a double-blind randomised placebo-controlled trial</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Alcohol Dependence</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Addiction</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>12-week intervention comparing oral baclofen 10mg t.i.d versus oral baclofen 20mg t.i.d. for the treatment of alcohol dependence, and incorporating a manualised behavioural therapy for all participants.</interventions>
    <comparator>12-week placebo for the treatment of alcohol dependence, and incorporating a manualised behavioural therapy for all participants.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduction in the proportion of heavy drinking days across the 12-week treatment period compared to baseline drinking</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number and severity of side-effects reported across the 12-week treatment period</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Reduction in self-reported anxiety and craving</outcome>
      <timepoint>At week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in liver function biomarkers (AST, ALT, GGT, bilirubin).</outcome>
      <timepoint>At week 4 and week 12.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DMS-IV criteria for alcohol dependence; Meets criteria for current heavy drinking; Can provide informed written consent; 3-days abstinence prior to treatment; Desires abstinence or to greatly reduce alcohol consumption; Has stable residence and can provide collateral contact details. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Clinically significant medical disease that might interfere with the evaluation of the study medication or present a safety concern; Clinically significant psychiatric illness or substance use disorder other than alcohol or nicotine dependence or cannabis abuse; Concurrent use of any psyhotropic medication (except subjects on stable antidepressant doses &gt; 2 months); Concurrent use of anticonvulsants, insulin or oral hypoglycemics, History of complicated alcohol withdrawal; Extremely abnormal LFTs; Women who are pregnant or breadfeeding; Requiring inpatient or more intense outpatient treatment for alcohol dependence; Court-mandated participation in alcohol treatment or impending incarceration.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants assigned consecutive identification numbers and given corresponding study medications from sealed packages prepared by a third party, idependent to the research.</concealment>
    <sequence>Shuffled treatment-group allocation cards in sealed envelopes with identification numbers only.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/05/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>42</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Sydney South West Area Health Service</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>SSWAHS</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Universita Cattolica Del Sacro Cuore</fundingname>
      <fundingaddress />
      <fundingcountry>Italy</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal Prince Alfred Hospital</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Sydney</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>National Drug and Alcohol Research Centre</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Ethics application submitted and responses to comments are being drafted presently.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Paul Haber</name>
      <address>Drug Health Services
Royal Prince Alfred Hospital
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95156419</phone>
      <fax>+61 2 95158970</fax>
      <email>phaber@mail.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof. Paul Haber</name>
      <address>Drug Health Services
Royal Prince Alfred Hospital
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95156419</phone>
      <fax>+61 2 95158970</fax>
      <email>phaber@mail.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>